NCT03698864View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 7, 2018

Primary Completion Date

February 25, 2020

Study Completion Date

February 25, 2020

Conditions
Necrobiosis Lipoidica
Interventions
DRUG

PCS499

PCS499 900mg twice a day with food

Trial Locations (2)

15213

Processa Investigational Site, Pittsburgh

19104

Processa Investigational Site, Philadelphia

Sponsors
All Listed Sponsors
lead

Processa Pharmaceuticals

INDUSTRY

NCT03698864 - A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica | Biotech Hunter | Biotech Hunter